You are here: Industry Insights > Market News > Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

expresspharmaJuly 12, 2021

Tag: Unichem , Januvia , Sitagliptin

Favorites

Unichem Laboratories has received tentative approval for ANDA of Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (USFDA) for a generic version of Januvia (sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, of Merck Sharpe and Dohme Corp (Merck).

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The product will be commercialised from Unichem’s Goa Plant on receipt of full approval.

Previous:Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes

Next:ICMR proposes clinical trial along with Oxford University to evaluate COVID-19 therapy

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>